A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug ...

Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for expanded use to treat moderate Alzheimer’s ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Elecsys Phospho-Tau 217 (pTau217), a blood-based biomarker test that can help distinguish Alzheimer’s disease ...

Nearly half of some 200 mild-to-moderate Alzheimer’s patients treated with oral simufilam for one year showed gains in cognitive tests.

Treatment with lecanemab (BAN2401), an experimental amyloid-targeting antibody, significantly slowed the progression of dementia symptoms among people with early Alzheimer’s disease in the Phase 3 ...

Foralumab helped to normalize microglial cell activity - tied to Alzheimer's progression - in the mice, leading to signs of better cognition.

Consider the following before gently correcting your loved one: The present stage of dementia and your loved one’s ability to process information. Is the behavior connected to dementia, or was it ...

Potential stroke therapy 3K3A-APC, about to enter a Phase 3 trial, may also help protect the brain against Alzheimer's and other dementias.

In a significant decision, the FDA approved Adulhelm (aducanumab) as a first targeted Alzheimer's treatment, and first new therapy since 2003.

Moderate stage Alzheimer's is the second and longest stage of this brain disease, likely marked by increased forgetfulness, confusion, and trouble speaking.

In early-stage Alzheimer's, changes in abilities or behavior may be minor and only noticeable to family and close friends. Some symptoms typify this stage.

For the first time, the beneficial effects of pure maple syrup were included in the natural products that protect brain cells against the neural damage found in patients with Alzheimer’s disease. Dr.